Seres Therapeutics
MCRB
79 hedge funds and large institutions have $227M invested in Seres Therapeutics in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 37 increasing their positions, 15 reducing their positions, and 9 closing their positions.
147% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 15
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
3% more funds holding
Funds holding: 77 → 79 (+2)
0.11% more ownership
Funds ownership: 4.6% → 4.71% (+0.11%)
12% less capital invested
Capital invested by funds: $258M → $227M (-$30.4M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $144K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$2.27M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$2.27M |
| 3 |
Squarepoint
New York
|
+$808K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$737K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$654K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.41M |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$612K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$402K |
| 4 |
MS
Maven Securities
St Helier,
Jersey
|
-$395K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$340K |
MCRB Hedge Fund Activity: Q4 2019 in Review
79 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q4 2019, worth a combined $227M — down 12% from $258M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new MCRB positions and 9 closed out — a net gain of 2 holders — while 37 added to existing stakes and 15 trimmed.
The largest buyer was Nikko Asset Management Americas, adding an estimated $2.27M. The largest seller was Fidelity Investments, cutting an estimated $2.41M.
- 79 institutional investors held Seres Therapeutics (MCRB) as of Q4 2019, up from 77 in Q3 2019.
- Funds reported $227M of Seres Therapeutics stock for Q4 2019, down 12% quarter-over-quarter.
- 11 funds opened new Seres Therapeutics positions in Q4 2019 and 9 closed out, a net change of +2 holders.
- The largest Seres Therapeutics buyer in Q4 2019 was Nikko Asset Management Americas, an estimated $2.27M added.
- The largest Seres Therapeutics seller in Q4 2019 was Fidelity Investments, an estimated $2.41M sold.
Based on aggregated 13F filings for Q4 2019.